{"disease":{"id":"hepatic-impairment","name":"hepatic impairment"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04271098","title":"The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries","phase":"","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","has_results":false},{"nct_id":"NCT03534843","title":"A Comparison Between Child-Pugh and Albumin-Bilirubin Scores","phase":"","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05484206","title":"Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Vir Biotechnology, Inc.","has_results":false},{"nct_id":"NCT06179368","title":"Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04469920","title":"Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Zydus Therapeutics Inc.","has_results":false},{"nct_id":"NCT04643795","title":"Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Madrigal Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05624944","title":"A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Taisho Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05765344","title":"Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05731804","title":"Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Jiangsu Simcere Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04208165","title":"PVB Versus TAP in Hepatic Patients Undergoing Laparoscopic Cholecystectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Theodor Bilharz Research Institute","has_results":false},{"nct_id":"NCT07219550","title":"A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04480827","title":"Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Galmed Research and Development, Ltd.","has_results":true},{"nct_id":"NCT05595109","title":"Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":56,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT04993157","title":"Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02998775","title":"Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT05009680","title":"A Single and Repeat Dose Trial in Participants With Hepatic Impairment","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Galecto Biotech AB","has_results":false},{"nct_id":"NCT03902002","title":"A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05835180","title":"A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Sagimet Biosciences Inc.","has_results":false},{"nct_id":"NCT01732263","title":"Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07486102","title":"A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT01429337","title":"PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03048448","title":"Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01465412","title":"A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03816631","title":"A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Janssen-Cilag International NV","has_results":false},{"nct_id":"NCT04573582","title":"Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04225936","title":"A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03742882","title":"A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT03824678","title":"Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT06985615","title":"A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05724693","title":"Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03983161","title":"A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT05599932","title":"Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05078580","title":"Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05935033","title":"A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT05753592","title":"A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04332432","title":"A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Galectin Therapeutics Inc.","has_results":false},{"nct_id":"NCT03722823","title":"A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT06425198","title":"Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07428525","title":"A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05436912","title":"A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT03706898","title":"Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Viriom","has_results":false},{"nct_id":"NCT05098054","title":"A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06841315","title":"A Varegacestat Hepatic Impairment Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Immunome, Inc.","has_results":false},{"nct_id":"NCT06812780","title":"A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04166942","title":"KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Kadmon, a Sanofi Company","has_results":false},{"nct_id":"NCT05919069","title":"A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01563562","title":"Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05684653","title":"Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT05891158","title":"A Study About Fazirsiran in People With and Without Liver Problems","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05917938","title":"A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}